Physician profile
Ashley C Record
NPI 1982894374
$6,223.21
in general payments reported to CMS, 2019-2025
24 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $41.09 · 2021: $59.08 · 2022: $1,407 · 2023: $1,492 · 2024: $1,128 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,906 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,906.49 |
| Education | $164.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,057.64 | 2019-2025 | |
| Janssen Biotech, INC. | $825.81 | 2019-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $646.22 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $630.81 | 2022-2025 | Otezla, Otezla |
| Leo Pharma INC. | $371.54 | 2021-2025 | Adbry, Anzupgo |
| Almirall LLC | $357.44 | 2019-2025 | Klisyri, Seysara |
| Pfizer INC. | $302.48 | 2019-2025 | |
| Ucb, INC. | $291.15 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $288.75 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $222.11 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $200.21 | 2022-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $169.92 | 2022-2025 | Sotyktu |
| Hill Dermaceuticals, INC. | $167.80 | 2023-2025 | Tolak |
| Novartis Pharmaceuticals Corporation | $165.93 | 2019-2023 | |
| Incyte Corporation | $162.37 | 2023-2025 | Opzelura |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $66.14 | 2023-2024 | Vtama |
| Celgene Corporation | $59.84 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.93 | 2019-2023 | Arazlo, Jublia |
| Biofrontera INC. | $52.78 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $41.27 | 2022-2025 | |
| Dermira, INC. | $38.84 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.26 | 2025 | Spevigo |
| Arcutis Biotherapeutics, INC. | $16.15 | 2023 | |
| Epi Health, LLC | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Record listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.